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Abstract
Purpose Bisphosphonates (BPs) are antiresorptive drugs
that provide important effects on bone turnover. The key
to the high efficiency of BPs is their affinity for bone tissue,
and their chemical structure provides their molecular mech-
anism of action. BPs are widely used to treat a variety of
diseases that cause excess bone resorption, such as bone
metastasis, hypercalcaemia due to malignancy and Paget’s
disease. The goal of this study was to assess whether the
bisphosphonate (Pamifos®) present in bone cement has any
effect on bone turnover. In this paper, we present changes in
cytokine levels in the serum of rats treated surgically.
Methods Research was performed on 40 adult male Wistar
rats. The rats were divided into four groups: two control
groups (A, B) and two experimental groups (C, D). Bone in
rats in the experimental groups was implanted with BP-
enriched cement, whereas bone in control-groups rats was
implanted with clean cement (without BPs).
Results We found a higher concentration of tumour necrosis
factor alpha (TNF-α) three weeks after surgery in rats
implanted with BP-enriched cement compared with rats
implanted with clean cement. After six weeks of treatment,
TNF-α levels decreased significantly in rats treated with
BP-enriched cement, whereas the control group experienced
an increase in TNF-α. The concentration of osteoprotegerin
ligand (OPG) was higher in rats with BP implants. We found
high levels of receptor activator of nuclear factor kappa-B
ligand (RANKL) in rats after implantation of cement with-
out BP in both groups.
Conclusions We conclude that use of bisphosphonate
(Pamifos®), which is present in bone cement, has an effect
on bone turnover in that BPs stimulate an increase in OPG
and a decrease in RANKL in the bone microenvironment
and thus may be an important component of mechanisms
that reduce bone resorption. Therefore, the use of BP-
enriched cement implants appears to be justified.
Introduction
Bisphosphonates (BPs) are antiresorptive drugs that provide
an important effect on bone turnover. There are increasing
reports of the beneficial action of BPs not only on achieving
better bone mineral density (BMD) but also on improving
bone microarchitecture, strength and, consequently, quality.
The key to the high efficiency of BPs is its affinity for bone
tissue, and their chemical structure provides their molecular
mechanism of action. BPs are stable pyrophosphate ana-
logues with a phosphorus–carbon–phosphorus (P-C-P)
structure that have a high affinity for hydroxyapatite (calci-
um ions) [1]. BPs are also potent inhibitors of bone resorp-
tion [2] and are widely used to treat a variety of diseases that
cause excess bone resorption, such as bone metastasis,
hypercalcaemia from malignancy and Paget’s disease [3,
4]. It has been demonstrated that several types of BPs are
useful for treating postmenopausal and other forms of oste-
oporosis [5, 6]. BPs are classified into two groups, nitrogen-
containing bisphosphonates (NBPs) and non-NBPs, each
with different mechanisms of action. NBPs, such as alendr-
onate, risedronate, ibandronate and pamidronate (PAM), act
on the cholesterol pathway by inhibiting diphosphate syn-
thase in the mevalonate pathway [7, 8]. The non-NBPs, such
as clodronate and etidronate, are transformed metabolically
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into cytotoxic adenosine triphosphatase (ATP) analogues that
inhibit ATP-dependent intracellular enzymes [9]. Because
BPs have an affinity for bone mineral, they act specifically
on bone. During bone resorption by osteoclasts, the ingestion
of BPs interferes with specific intracellular processes, which
impair osteoclast function and ultimately cause apoptosis or
cell death [10]. BPs that resemble pyrophosphate more closely
(e.g. clodronate) can be incorporated into nonhydrolysable
analogues of ATP that may inhibit ATP-dependent intracellu-
lar enzymes. NBPs (e.g. alendronate) inhibit enzymes in the
mevalonate pathway, thereby preventing biosynthesis of es-
sential compounds for protein prenylation, which blocks the
function of key regulate proteins [11]. Some studies suggest
that BPs that resemble the pyrophosphate group have anti-
inflammatory effects, whereas aminobisphosphonates have
some proinflammatory effects [12]. In summary, BPs regulate
osteoblastic functions such as proliferation and differentiation,
prevent osteoblast apoptosis, modulate osteoblastic produc-
tion of extracellular matrix proteins and regulate osteoblastic
expression and secretion of various growth factors and cyto-
kines [13].
Several recent studies, both preclinical and clinical, have
focused on the potential application of BPs to the problems
of bone catabolism encountered in orthopaedics. These
studies indicate that the most promising roles for BPs are
prevention of bone collapse following osteonecrosis and in
enhancing implant fixation. Combination therapies that have
both bone antiresorptive and anabolic agents also show
great promise for orthopaedic applications [14].
The microarchitectural adaptation of bone mass and
BMD due to osteoclast-mediated resorption is of great clin-
ical importance for many bone diseases, including osteopo-
rosis and osteoarthritis. During bone resorption, trabecular
bone microstructure is altered, often influencing functional
strength and the integrity of cartilage support. Osteoclast
formation (osteoclastogenesis) is induced in the presence of
macrophage colony stimulating factor (M-CSF) when the
membrane-bound factor receptor activator of nuclear factor
kappa-B ligand (RANKL) binds to its receptor, RANK.
RANKL is a protein of 317 amino acids that belongs to
the tumour necrosis factor (TNF) superfamily and the mes-
senger RNA (mRNA) of which is largely expressed in bone,
bone marrow and lymphoid tissues. The predominant role of
this cytokine in bone physiology is the stimulation of oste-
oclastic differentiation/activation and the inhibition of oste-
oclast apoptosis [15]. The process of osteoclastogenesis can
be disturbed by local factors that interrupt RANKL–RANK
intercellular signalling [16]. One of these factors is OPG, a
soluble, circulating glycoprotein from the TNF-receptor
family. OPG present in an extracellular matrix can inhibit
osteoclastogenesis by binding with RANKL and blocking
its interaction with RANK on osteoclast precursors. OPG
blocks osteoclast differentiation, promotes apoptosis of
activated osteoclasts and reduces osteoclast adhesion to the
bone surface, with a net effect of reduced osteoclast activity
[17–19]. TNF-α exerts its biological effects by binding to
TNF type 1 receptor (TNF-R1) and type 2 receptor (TNF-
R2) [20, 21]. Both receptors are expressed in the lineages of
osteoclasts and osteoblasts [22]. TNF-α plays a central role
for inflammatory reaction [23, 24].
The goal of this study was to assess whether the
bisphosphonate (Pamifos®) that is present in bone cement
has any effect on bone turnover. In this paper, we present
changes in cytokine levels in the serum of rats treated
surgically. Anaesthetised rats were injected with cement that
was enriched with a BP.
Materials and methods
Animals Wistar CRL(WI)WU BR rats were obtained from
Mossakowski Medical Research Centre, Polish Academy of
Sciences. The experimental procedures were reviewed and
approved by the Bioethical Committee of Animal
Experimentation of the Medical University of Lublin.
Reagents Enzyme-linked immunosorbent assay (ELISA) kits
were purchased from BioVendor Research and Diagnostic
Products (Brno, Czech Republic). Bisphosphonate (Pamifos
60) was purchased from Vipharm (Warsaw, Poland). Bone
cement was purchased from CMW 1, DePuy International
Ltd, England.
Animal model Research was performed on 40 adult male
Wistar rats, the weight of which ranged from 120 g to 240 g.
The rats were divided into four groups: two control groups
(A, B) and two experimental groups (C, D). Bone in rats in
experimental groups was implanted with BP-enriched ce-
ment and in the control groups with clean bone cement
(without BP). Because experimental groups were operated
upon at a different time, each group had its own dedicated
control group. The animals were anaesthetised using thio-
pental with depth of anaesthesia being assessed by pedal
reflex. Each animal was then placed in the supine position,
and the skin over both tibial bones was shaved and disin-
fected. A skin incision was made over the proximal part of
the tibial bone. After exposure of the proximal tibia, freshly
mixed bone cement was pressurised into the bone canal
through a predrilled hole by using a syringe with a modified
needle. Twenty rats were given pure cement (control
groups) and the remaining 20 rats cement mixed with BP.
The wound was closed using Vicryl sutures and staples. At
three and six weeks after surgery, the rats were anaesthetised
using thiopental (30 mg/kg), and blood samples were taken
from the left ventricle. The samples were frozen in liquid
nitrogen and stored at −70 °C.
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Blood assays To determine biochemical markers, blood
samples were taken from the heart, preferably the ventricle,
and then punctured into pyrogen-free tubes containing hep-
arin (Endo Tube ET; Chromogenix, Mo¨ lndal, Sweden).
Plasma was immediately separated at 4 °C by centrifugation
at 180g for ten minutes and stored in pyrogen-free tubes
(N201 Test Tubes; Biowittaker, Walkersville, MD, USA) at
−80 °C. TNF-α, osteoprotegerin and rat soluble RANKL
(sRANKL) concentrations in blood serum were analysed
using an ELISA kit.
Statistical analysis
Statistical analyses were performed using one-way analyses of
variance (ANOVA). Post-hoc comparison of means was carried
out with Tukey’s test for multiple comparisons, when appro-
priate. For this case, all data are shown as the means ± standard
error (SEM). For cases with rejected hypothesis of normal
distribution or homogeneity of variance, nonparametric
Kruskal–Wallis ANOVA by Ranks multiple comparisons was
used. Data are shown as median with first and third quartiles.
Data were considered statistically significant at a confidence
limit of P<0.05. All statistical calculations were performed
using 10.0 STATISTICA software (StatSoft, Poland).
Results
We found a higher concentration of TNF-α three weeks after
surgery in rats implanted with BP-enriched cement compared
with rats implanted with cement without BP. After six weeks
of treatment TNF-α levels decreased significantly in rats
treated with a BP-enriched cement, whereas rats in the control
groups experienced an increase in TNF-α (Fig. 1). The result
is highly statistically significant (P=0.00). Post-hoc RIR
Tukey test was used to verify differences between groups.
Statistically significant differences between the groups studied
using BPs with cement were found three and six weeks after
surgery (P=0.000132). There were also statistically signifi-
cant differences between the control group and a BP group
six weeks after surgery (P=0.000127).
The results of the Kruskal–Wallis test [H (3, n=40)=
32.13, P=0.00] indicate a statically significant difference
between the level of OPG in the treatment groups. The
concentration of OPG, a natural antagonist of RANKL,
was higher in rats with BP implants (at both three and
six weeks after surgery) than in the control groups (Fig. 2)
. OPG level in the control group three weeks after the
treatment was significantly lower than in the test group with
BP implants (P=0.000101). Similar results were obtained
six weeks after surgery, where the level of OPG in the
control group was significantly lower than in the study
group (P=0.004897). Three weeks after the treatment, the
OPG concentration was four times higher in rats implanted
with cement containing BP (group C) than in the control
group (group A).
As described earlier in the paper, there was a statistically
significant difference in RANKL level, as we found high
levels of RANKL in rats after implantation of cement without
BP in both groups (A and B, Fig. 3). The highest RANKL
concentration, 8.23±0.97 pg/ml, was found six weeks after
surgery in the control group (B, P=0.00002).
Discussion
For healthy bone, the processes of the bone formation and
resorption should be in balance, thus guaranteeing relatively

































Fig. 1 Median level of tumour necrosis factor alpha (TNF-α) concen-
tration in rats’ serum after clean cement was implanted into the bone (a,
b) in comparison with rats implanted with bisphosphonate (BP)-





























Fig. 2 Median level of osteoprotegerin (OPG) concentration in rats’
serum after bone implantation with clean cement (a, b) in comparison
with rats implanted with bisphosphonate (BP)-enriched cement (c, d)
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process involves hormones and local mediators (growth
factors and cytokines) secreted by osteoblasts and osteo-
clasts. The local cytokine secretion may produce locally
high concentrations, so that they become effective [25].
Identification of the OPG/RANKL/RANK system as an
important mediator of osteoclastogenesis is a great achieve-
ment in the field of bone biology.
OPG is one factor inhibiting bone resorption; thus, when
its concentration is reduced, the resorption processes may
prevail and bone loss occurs. Bucay et al. reported that mice
lacking the OPG gene developed severe osteoporosis, with
multiple fractures and associated hypercalcaemia [26].
Recent in vitro studies have clearly demonstrated that oste-
oblastic lineage cells are targets for BPs and that these
compounds act to modulate important cellular functions of
osteoblasts, including proliferation, differentiation, synthe-
sis of extracellular matrix proteins and formation of miner-
alised nodules [27–29]. Earlier coculture studies have
suggested that the presence of osteoblastic lineage cells is
required in order for the antiresorptive effects of BPs to
occur [30] and proposed that this effect depends upon a
soluble factor that is secreted by osteoblasts and acts on
osteoclasts to inhibit their function, based on the capacity of
BP-conditioned osteoblastic medium to inhibit osteoclast
formation and activity [31, 32].
RANKL is both necessary and sufficient for osteoclast
formation and activation, whereas OPG, which is secreted
by osteoblastic lineage cells, blocks these effects by neutral-
ising RANKL [33]. TNF exerts osteoclastogenic properties
indirectly by stimulating RANKL in various cell types
[34, 35].
Our study demonstrates that local BP treatment can affect
the level of cytokines in the blood serum. We found low
levels TNF-α in serum of rats six weeks after implantation
into the bone of cement enriched with BP compared with
three weeks after the surgery. Recent evidence suggests that
TNF-α is not exclusively a catabolic modulator of bone
metabolism. Balga et al. described TNF-α as acting not only
as a stimulator of bone resorption but also as a possible
inhibitor for the development of osteoclasts in vitro [36].
The decrease in TNF-α levels in rats treated with BP
implants is therefore preferred for the process of bone for-
mation, whereas the effect of lower concentrations were
obtained when using only BP-enriched cement implants.
In rats implanted with clean bone cement, TNF-α levels in
serum six weeks after surgery significantly increased rela-
tive to the level observed three weeks after the operation.
The mutual activity of osteoclasts and osteoblasts ensures
a balance between bone resorption and formation during the
turnover of normal healthy bone. Osteoclast formation,
function and survival are regulated primarily by RANKL
and the two receptors to which it binds: RANK and OPG. In
healthy bone, the RANKL pathway facilitates the balance
between bone formation and resorption; however, an in-
crease in the level of RANKL promotes bone resorption
[37].
In our studies, we noted a reduction in RANKL serum
levels in rats six weeks after implantation of cement con-
taining BP compared with that recorded three weeks after
surgery, whereas concentration in the control group in-
creased from 5.7 pg/ml (three weeks after the operation) to
8.23 pg/ml (six weeks after the operation). There was also a
high level of OPG in serum both three and six weeks after
implantation of bone cement enriched with BP, whereas in
controls, OPG concentration was maintained at a much
lower level. Our results support the hypothesis that cement
enriched with BP may regulate important mediators in-
volved in osteoclastogenesis, such as RANKL synthesised
by osteoblasts [38], and may modulate OPG, a decoy recep-
tor of RANKL absorption, thus preventing RANK activa-
tion. Viereck et al. showed that the primary effect of BPs in
differentiated osteoblasts on the RANKL/OPG system is the
enhancement of OPG production [13]. They showed also
that the BPs pamidronate and zoledronic acid act directly on
human osteoblastic cells to increase OPG secretion, a potent
inhibitor of bone resorption. Research by Aspenberg et al.
and Jeppsson et al. showed that local used of a BP solution
increased bone ingrowth or new bone formation [39, 40].
However, that did not present the humoral response.
We conclude that use of bisphosphonate (Pamifos®)
in bone cement has an effect on bone turnover.
Stimulated by an increase in BP in OPG and a decrease
in RANKL in bone microenvironment may be an im-
portant component of the mechanisms that reduce bone
resorption. Therefore, the use of BP-enriched bone-


































Fig. 3 Median level of receptor activator of nuclear factor kappa-B
ligand (RANKL) concentration in rats’ serum after bone implantation
with clean cement (a, b) in comparison with rats implanted with
bisphosphonate (BP)-enriched cement (c, d)
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